Literature DB >> 16428703

Postinfectious cough: ACCP evidence-based clinical practice guidelines.

Sidney S Braman.   

Abstract

BACKGROUND: Patients who complain of a persistent cough lasting >3 weeks after experiencing the acute symptoms of an upper respiratory tract infection may have a postinfectious cough. Such patients are considered to have a subacute cough because the condition lasts for no >8 weeks. The chest radiograph findings are normal, thus ruling out pneumonia, and the cough eventually resolves, usually on its own. The purpose of this review is to present the evidence for the diagnosis and treatment of postinfectious cough, including the most virulent form caused by Bordetella pertussis infection, and make recommendations that will be useful for clinical practice.
METHODS: Recommendations for this section of the guideline were obtained from data using a National Library of Medicine (PubMed) search dating back to 1950, which was performed in August 2004, of the literature published in the English language. The search was limited to human studies, using the search terms "cough," "postinfectious cough," "postviral cough," "Bordetella pertussis," "pertussis infection," and "whooping cough."
RESULTS: The pathogenesis of the postinfectious cough is not known, but it is thought to be due to the extensive inflammation and disruption of upper and/or lower airway epithelial integrity. When postinfectious cough emanates from the lower airway, this is often associated with the accumulation of an excessive amount of mucus hypersecretion and/or transient airway and cough receptor hyperresponsiveness; all may contribute to the subacute cough. In these patients, the optimal treatment is not known. Except for bacterial sinusitis or early on in a B pertussis infection, therapy with antibiotics has no role, as the cause is not bacterial infection. The use of inhaled ipratropium may be helpful. Other causes of postinfectious cough are persistent inflammation of the nose and paranasal sinuses, which leads to an upper airway cough syndrome (previously referred to as postnasal drip syndrome), and gastroesophageal reflux disease, which may be a complication of the vigorous coughing. One type of postinfectious cough that is particularly virulent is that caused by B pertussis infection. When the cough is accompanied by paroxysms of coughing, posttussive vomiting, and/or an inspiratory whooping sound, the diagnosis of a B pertussis infection should be made unless another diagnosis is proven. This infection is highly contagious but responds to antibiotic coverage with an oral macrolide when administered early in the course of the disease. A safe and effective vaccine to prevent B pertussis is now available for adults as well as children. It is recommended according to CDC guidelines.
CONCLUSIONS: In patients who have a cough lasting from 3 to 8 weeks with normal chest radiograph findings, consider the diagnosis of postinfectious cough. In most patients, a specific etiologic agent will not be identified, and empiric therapy may be helpful. A high degree of suspicion for cough due to B pertussis infection will lead to earlier diagnosis, patient isolation, and antibiotic treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16428703     DOI: 10.1378/chest.129.1_suppl.138S

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  34 in total

Review 1.  Cough: an unmet clinical need.

Authors:  Peter V Dicpinigaitis
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

2.  Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines.

Authors:  Richard S Irwin; Michael H Baumann; Donald C Bolser; Louis-Philippe Boulet; Sidney S Braman; Christopher E Brightling; Kevin K Brown; Brendan J Canning; Anne B Chang; Peter V Dicpinigaitis; Ron Eccles; W Brendle Glomb; Larry B Goldstein; LeRoy M Graham; Frederick E Hargreave; Paul A Kvale; Sandra Zelman Lewis; F Dennis McCool; Douglas C McCrory; Udaya B S Prakash; Melvin R Pratter; Mark J Rosen; Edward Schulman; John Jay Shannon; Carol Smith Hammond; Susan M Tarlo
Journal:  Chest       Date:  2006-01       Impact factor: 9.410

3.  Phenotypic presentation of chronic cough in children.

Authors:  Ahmad Kantar
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 4.  Clinically Diagnosing Pertussis-associated Cough in Adults and Children: CHEST Guideline and Expert Panel Report.

Authors:  Abigail Moore; Anthony Harnden; Cameron C Grant; Sheena Patel; Richard S Irwin
Journal:  Chest       Date:  2018-10-12       Impact factor: 9.410

5.  HSP90 inhibitor geldanamycin reverts IL-13- and IL-17-induced airway goblet cell metaplasia.

Authors:  Alejandro A Pezzulo; Rosarie A Tudas; Carley G Stewart; Luis G Vargas Buonfiglio; Brian D Lindsay; Peter J Taft; Nicholas D Gansemer; Joseph Zabner
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

6.  Chronic cough: the allergist's perspective.

Authors:  Sheldon L Spector
Journal:  Lung       Date:  2007-10-22       Impact factor: 2.584

7.  Extrathoracic airway hyperresponsiveness as a mechanism of post infectious cough: case report.

Authors:  Nicole M Ryan; Peter G Gibson
Journal:  Cough       Date:  2008-08-04

8.  High prevalence of gastroesophageal reflux symptoms in patients with both acute and nonacute cough.

Authors:  Yoshihisa Urita; Toshiyasu Watanabe; Hiroki Ota; Motohide Iwata; Yosuke Sasaki; Tadashi Maeda; Takamasa Ishii; Makie Nanami; Asuka Nakayama; Hirohito Kato; Kazuo Hike; Noriko Hara; Masaki Sanaka; Yoko Nagai; Shuji Watanabe; Kazushige Nakanishi; Hitoshi Nakajima; Motonobu Sugimoto
Journal:  Int J Gen Med       Date:  2008-11-30

Review 9.  Coughing precipitated by Bordetella pertussis infection.

Authors:  Matthew Hewitt; Brendan J Canning
Journal:  Lung       Date:  2010-01       Impact factor: 2.584

10.  Treatments for subacute cough in primary care: systematic review and meta-analyses of randomised clinical trials.

Authors:  Benjamin Speich; Anja Thomer; Soheila Aghlmandi; Hannah Ewald; Andreas Zeller; Lars G Hemkens
Journal:  Br J Gen Pract       Date:  2018-09-10       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.